Exact Sciences secures colorectal cancer test rights from Freenome in a $75M agreement with up to $700M milestone payouts.

Cancer vaccine experts are worried that if the Trump administration takes a hostile posture towards mRNA broadly, cancer ...

MADISON, Wis. -- Exact Sciences is laying off 4% of its overall workforce, including 80 positions in Madison. Approximately ...

Full-year 2025 revenue and adjusted EBITDA guidance were raised, reflecting strong commercial execution and new product launches. These 10 stocks could mint the next wave of millionaires › Exact ...

Madison-based Exact Sciences is cutting about 4% of its overall workforce, impacting about 200 positions in Wisconsin.

Exact Sciences acquires exclusive rights to current and future versions of Freenome's blood-based colorectal cancer screening tests. Continue reading this article with a Barron’ ...

Diagnostic company Exact Sciences Corporation (NASDAQ:EXAS) reported Q2 CY2025 results , with sales up 16% year on year to ...

MADISON, Wis. (AP) — MADISON, Wis. (AP) — Exact Sciences Corp. (EXAS) on Wednesday reported a loss of $1.2 million in its second quarter. The Madison, Wisconsin-based company said it had a loss of 1 ...

Exact Sciences is paying $75 million for exclusive rights to a blood-based "liquid biopsy" screening test from rival firm Freenome ...

Exact Sciences bought the rights to Freenome's blood-based colon cancer test. The news could spark Exact Sciences stock.

Analysts anticipate Exact Sciences to report an earnings per share (EPS) of $0.02. Anticipation surrounds Exact Sciences's ...

Baron Funds, an investment management company, released its “Baron Health Care Fund” second-quarter 2025 investor letter. A ...